Analysts? Most of them don't know their a$$ from a whole in the wall. They are uneducated, crook and looking for some sheep to follow them. I wonder why all these banks and financial institutions with many analysts in their position could not hint the smallest thing about subprime. Analysts are jokers. At the same time Pacific Growth Equities was saying "In our view, Colazal continues to perform well in light of Lialda's competitive presence. Colazal s #-ASA market share was ##.#% in May (off #.#% over April); meanwhil emarket-leader Asacol lost #.#% of its sh are. Endo Pharmaceutical s (ENDP: Nasdaq;"
Lialda could take some market share from other companies but Colazal will continue to stand firm and growing with new 2 times a day and Eisai’s contract.
Colazal revenue Q3 was way above its Q3 2006. What happened in analysts prediction or are they still guessing? SLXP is growing in different areas. Colazal is only one of many SLXP drugs. Colazal generic is not easy to make and it won’t make any money with different companies are coming up with two times and one time a day drug. After all, SLXP will launch its 2 times a day Colazal by early May and generic cannot touch it for at least 15 yeas. Eisai 600 sales reps never accept promoting Colazal if the picture was that dark. Eisai has proven sales team and the impressive share of voice in the marketplace with $2.6 billion sales
Although alot of the price decline reflects new generic competition ----it may not be over....New generic supposedly coming out at naturally a better price---consumer is broke---insurance companies are cheap and pbm `s will likely redirect DR. & Rx to the less expensive brand. It usually gets worse than we expect